Eylea (aflibercept), as compared to Avastin (bevacizumab) or Lucentis (ranibizumab), provided greater visual improvement for diabetic macular edema (DME), when vision was 20/50 or worse at the start of the NIH-supported clinical trial. However, investigators found that all the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32, and nor did they find any major differences in the safety of the three drugs. This comparative effectiveness ...
No comments:
Post a Comment